EX-99.1 2 dp11443_ex9901.htm
Exhibit 99.01
 
Hampshire International Business Park
Chineham  Basingstoke
Hampshire RG24 8EP
United Kingdom
Tel +44 (0)1256 894000
Fax +44 (0)1256 894708
www.shire.com
   
Press Release
  
 
 


Correction - Results of the Annual General Meeting held on September 24, 2008
Correction for the announcement made on September 24, 2008. Two paragraphs were truncated from the original announcement.
 

 
Dublin, Ireland – September 25, 2008 – Shire Limited (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announces that at its Annual General Meeting today, all resolutions contained in the notice of meeting were duly passed and the results of the poll are as follows:

 
For*
Against
Withheld**
1.
To elect Mr Matthew Emmens as a Director of the Company
301,376,910
  
4,696,170
  
25,441,808
  
2.
To elect Mr Angus Russell as a Director of the Company
331,225,599
  
138,229
  
151,060
  
3.
To elect Mr Graham Hetherington as a Director of the Company
331,234,635
  
127,173
  
153,080
  
4.
To elect Dr Barry Price as a Director of the Company
328,858,454
  
2,501,778
  
154,656
  
5.
To elect Mr David Kappler as a Director of the Company
330,945,634
  
412,470
  
156,784
  
6.
To elect Dr Jeffrey Leiden as a Director of the Company
331,221,109
  
138,828
  
154,951
  
7.
To elect Mr Patrick Langlois as a Director of the Company
330,949,493
  
412,089
  
153,306
  
8.
To elect Ms Kate Nealon as a Director of the Company
331,014,606
  
346,949
  
153,333
  
9.
To elect Mr David Mott as a Director of the Company
327,884,774
  
2,101,928
  
1,528,186
  
10.
To elect Dr Michael Rosenblatt as a Director of the Company
331,232,603
  
126,815
  
155,470
  
11.
To re-appoint Deloitte & Touche LLP as Auditors of the Company
327,634,578
  
1,301,388
  
2,578,922
  
 
 

Registered in Jersey, No. 99854, 22 Grenville Street, St Helier, Jersey JE4 8PX
 
 
 
 
 
 
12.
To authorise the Audit, Compliance and Risk Committee to determine the remuneration of the Auditors
331,225,599
  
1,470,679
  
159,584
  
13.
To authorise the allotment of shares
328,104,104
  
3,189,130
  
221,654
  
14.
To authorise the disapplication of pre-emption rights
329,760,418
  
1,575,955
  
178,515
  
15.
To authorise market purchases
330,598,450
  
729,745
  
186,693
  
16.
To change the name of the Company to Shire plc
331,323,817
  
31,609
  
159,462
  

 
*  These figures include discretionary votes
** A vote “withheld” is not a vote in law and is not counted in the calculation of the votes “for” or “against” a resolution.

Two copies of all resolutions passed, other than resolutions concerning ordinary business, will shortly be submitted to the UK Listing Authority and will be available for inspection at the UK Listing Authority's Document Viewing Facility, which is situated at the Financial Services Authority, 25 The North Colonnade, Canary Wharf, London E14 5HS.

The change of name of the Company to Shire plc is expected to become effective on October 1, 2008, following the registration of the change with Companies Registry in Jersey.


 
For further information please contact:

Investor Relations
Cléa Rosenfeld (Rest of the World)
+44 1256 894 160
 
Eric Rojas (North America)
+1 484 595 8252
Media
Jessica Mann (Rest of the World)
+44 1256 894 280
 
Matthew Cabrey (North America)
+1 484 595 8248
 
Jessica Cotrone (North America)
+1 617 613 4640

Notes to editors

SHIRE LIMITED

Shire’s strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician.  Shire focuses its business on attention deficit hyperactivity disorder (ADHD), human genetic therapies (HGT) and
 
 

Registered in Jersey, No. 99854, 22 Grenville Street, St Helier, Jersey JE4 8PX
 
 
 
 
 
 
gastrointestinal (GI) diseases as well as opportunities in other therapeutic areas to the extent they arise through acquisitions.  Shire’s in-licensing, merger and acquisition efforts are focused on products in specialist markets with strong intellectual property protection and global rights.  Shire believes that a carefully selected and balanced portfolio of products with strategically aligned and relatively small-scale sales forces will deliver strong results.

For further information on Shire, please visit the Company’s website: www.shire.com.
 
 

Registered in Jersey, No. 99854, 22 Grenville Street, St Helier, Jersey JE4 8PX